18 results about "Moxifloxacin" patented technology

The invention relates to a method for detecting six second-line antituberculous drugs by high performance liquid chromatography. The method comprises the following steps: providing an internal standard stock solution and a standard stock solution of six second-line antituberculosis drugs; preparing an internal standard working solution and a standard curve working solution by utilizing the diluent; preparing a solution of a product to be detected by using the Tianlongitudinal sample extraction liquid TZ-002; a liquid chromatograph is used for detection, and the conditions are as follows: a mobile phase A is a Tianlongitudinal sample releasing agent TZ-D004; a mobile phase B is acetonitrile; a mobile phase C is water; and gradient elution. According to the method, the plasma concentration of the second-line antituberculous drug taken by a tuberculosis patient is measured by applying the reversed-phase high-performance liquid chromatography, the cost is relatively low, the analysis time is short, the sensitivity is high, and the accuracy is high. The kit can be used for simultaneously detecting the blood concentration of six second-line antituberculosis drugs such as isopropylthioamide, levofloxacin, linezolid, moxifloxacin, deramanib and bedaquiline in human serum, and is expected to provide a more reliable basis for clinicians to adjust the dosage of the antituberculosis drugs.

The invention relates to an optimer-based electrochemical biosensor for use in the determination of SARS-CoV-2 S1 protein and Moxifloxacin as well as the method for its operation. The invention also includes an application of said method for the diagnosis of disease and the determination of drugs. In this context, SARS-CoV-2 S1 protein and Moxifloxacin were selected as target analytes and electrochemical analyses of these target analytes were performed using optimer-based procedure and electrochemical impedance spectroscopy technique.

The application discloses a preparation method and application of a fluorescence-enhanced probe for rapidly detecting moxifloxacin and norfloxacin, and belongs to the technical field of rapid antibiotic detection. The fluorescence-enhanced probe is prepared from p-aminosalicylic acid and L-cysteine by a hydrothermal method, and the optimal preparation process is that the p-aminosalicylic acid and the L-cysteine with a mass ratio of 4:1 are dissolved in anhydrous ethanol, and then heated at 200 DEG C for 14 hours. Moxifloxacin and norfloxacin can significantly enhance the fluorescence intensity of the fluorescence probe at 520 nm and 460 nm, respectively, and have a good linear relationship with the concentration. The application has the advantages of simple operation, low cost, rapid detection, high sensitivity, high selectivity, wide detection range and low detection limit, and can realize on-site rapid detection of moxifloxacin and norfloxacin in water and milk.

The present invention relates to the technical field of chemical synthesis, and in particular to a chiral nickel phosphine (II) complex with a one-dimensional supramolecular structure, and a preparation method and application thereof. A chiral nickel phosphine (II) complex with a one-dimensional supramolecular structure, the chemical formula of which is Ni(TFM-Josiphos)Cl2, wherein TFM-Josiphos is (R)-1-{(S)-2-[bis(3,5-di-trifluoromethylphenyl)phosphino]ferrocenyl}ethylbis(trifluoromethyl)phosphine, the chiral nickel phosphine (II) complex crystal of the present invention belongs to the orthorhombic system, the P222 space group, the unit cell parameters are a=17.3946(7)Å, b=23.1260(7)Å, c=27.7424(6)Å, α=90°, β=90°, γ=90°, V=10736.8(3)Å 3 The preparation method of the chiral phosphine nickel (II) complex of the present invention is simple and convenient to operate, with high purity and good reproducibility. The chiral phosphine nickel (II) complex of the present invention has good thermal stability, exhibits good catalytic performance in the asymmetric catalytic hydrogenation reaction of the side chain of moxifloxacin, a chiral drug intermediate, and has good application prospects.

The invention discloses a sulfur-doped bi-metal cobalt cerium oxide Fenton-like catalyst and a preparation method and application thereof.The sulfur-doped bi-metal cobalt cerium oxide Fenton-like catalyst is a sulfur-doped cobalt cerium composite oxide, and in the sulfur-doped bi-metal cobalt cerium oxide Fenton-like catalyst, the Co element content is 20-24 wt%, the Ce element content is 50-56 wt%, the O element content is 20-22 wt%, and the balance is a carrier. The content of the S element is 1-4 wt%. According to the sulfur-doped bimetallic cobalt cerium oxide Fenton-like catalyst disclosed by the invention, peroxyacetic acid is activated to generate organic oxygen free radicals, and 90.5% of moxifloxacin can be degraded within 15 minutes; and the composite material has a good degradation effect on pollutants of polycyclic aromatic compounds such as ofloxacin, gatifloxacin, norfloxacin, tetracycline, o-nitrophenol, naproxen and the like.

The invention relates to a 4-oxopyrrolidine derivative as well as a preparation method and application thereof. The structural formula of the 4-oxopyrrolidine derivative is # imgabs0 #, wherein R1 and R2 are independently selected from straight-chain or branched-chain C1-C18 alkyl groups; y is selected from a fluorine atom, a chlorine atom, a bromine atom, a methylsulfonyl group, a p-toluenesulfonyl group, a nitrobenzene methylsulfonyl group and a trifluoromethylsulfonyl group. The preparation method comprises the following steps that a compound shown in a formula (II) and a compound shown in a formula (III) react in an aprotic solvent for 20-28 h under the alkaline condition, after aftertreatment, a compound shown in a formula (I) is obtained, and the reaction route is as follows: # imgabs1 #. Compared with the prior art, the preparation method is high in yield, low in by-product proportion, low in solvent cost and suitable for industrial production. The method can be used for preparing the moxifloxacin intermediate.

The invention discloses a moxifloxacin hapten, antigen and antibody as well as a preparation method and application thereof, and belongs to the technical field of small molecule immunodetection.The moxifloxacin hapten, antigen and antibody are obtained by introducing an alkyl connecting arm-(CH2) n-NH2 with a specific length to a secondary amino group, away from a quinolone mother nucleus, of moxifloxacin, according to the present invention, the carbostyril is introduced into the molecule so as to endow the molecule with chemical operability on the premise of not disturbing the pharmacophore of the quinolone mother nucleus, such that the molecule can efficiently couple the carrier protein and induce the generation of the high affinity and high specificity antibody so as to finally construct the immunodetection system suitable for the treatment drug monitoring and the bedside instant detection scene;

This invention discloses the application of *Gastrococcus xanthophylloides* in regulating intestinal bile acid metabolism disorders, including *Gastrococcus xanthophylloides* (… Ruminococcus flavefaciens The application of this invention in the preparation of compositions for regulating intestinal bile acid metabolism disorders, wherein the compositions promote the conversion of primary bile acids to secondary bile acids, wherein the primary bile acids include cholic acid and chenodeoxycholic acid, and the secondary bile acids include deoxycholic acid and lithocholic acid; wherein the intestinal bile acid metabolism disorders include metabolic disorders caused by antibiotics, wherein the antibiotics include one or more of moxifloxacin and metronidazole; wherein the compositions can be health products, pharmaceuticals, or feed; and wherein the active ingredient of the compositions includes xanthospirococcus flavus.

A novel ophthalmic treatment for ocular pain, such as epithelial defects of the cornea or conjunctiva, which includes a liquid or gel-based formulation containing a topical anesthetic mixed with an antibiotic. The two substances are combined according to a preferred volumetric ratio wherein the anesthetic retains its efficacy in alleviating the patient's pain, while also diluting the anesthetic enough to permit patients to self-administer the eyedrops without clinical supervision. In a preferred example, the antibiotic comprises moxifloxacin (or an equivalent fluoroquinolone-class antibiotic) at an initial concentration of about 0.5%, and the anesthetic comprises proparacaine hydrochloride at an initial concentration of about 0.5%. Preferably, the volumetric ratio of the antibiotic and an excipient relative to the anesthetic is between about 5:1 and about 15:1, such that the antibiotic and the excipient dilute the anesthetic down to a relative concentration of about 0.030% to about 0.085%.

The invention discloses a moxifloxacin nano drug delivery system as well as a preparation method and application thereof, and the moxifloxacin-loaded infected microenvironment lipase response nano drug delivery system is constructed on the basis of a comprehensive strategy of drug-assistant synergistic sensitization and antibiosis, improvement of permeability of a bacterial outer membrane, inhibition of activity of a bacterial efflux pump and removal of a biofilm. The sensitivity of moxifloxacin to multi-drug-resistant pseudomonas aeruginosa is enhanced, the pathogenicity of bacteria is reduced, and the risks of infection recurrence and drug resistance are reduced while the infection clearance rate is increased. And the antibiotic adjuvant adopts natural biodegradable epsilon-polylysine, so that the side effect of lung inhalation is reduced, and the biological safety of the nano-drug delivery system is improved.

The invention discloses a pharmaceutical composition containing a substance X, a substance Y and an optional substance z and application of the pharmaceutical composition in preparation of drugs for treating diseases caused by mycobacterium tuberculosis. The substance X is a compound I or a pharmaceutically acceptable salt thereof, and the substance Y and the substance Z are selected from pyrazinamide, linezolid, moxifloxacin, preremanib or deramanib. # imgabs0 #

A novel ophthalmic treatment for corneal abrasions includes a liquid eyedrop containing a topical anesthetic mixed with an antibiotic. The two substances are combined according to a preferred volumetric ratio wherein the anesthetic retains its efficacy in alleviating the patient's pain, while also diluting the anesthetic enough to permit patients to self-administer the eyedrops without clinical supervision. In a preferred example, the antibiotic comprises moxifloxacin (or an equivalent fluoroquinolone-class antibiotic) at an initial concentration of about 0.5%, and the anesthetic comprises proparacaine hydrochloride at an initial concentration of about 0.5%. Preferably, the volumetric ratio of the antibiotic to the anesthetic is between about 5:1 and about 15:1, such that the antibiotic dilutes the anesthetic down to a relative concentration of about 0.030% to about 0.085%.

The application relates to a high-activity electrode and a preparation method thereof and application of the electrode in sewage treatment. The preparation method is as follows: Sn source, Sb source and Tb source are configured into a mixed solution, the Tb-Sn-Sb sol is obtained after ultrasonic treatment and standing and aging, the Tb-Sn-Sb sol is uniformly coated on the surface of an electrode substrate, and the high-activity titanium-based tin dioxide-antimony electrode is prepared through heat treatment at a specific temperature. The application finds that, for the first time, the rare earth element Tb is doped in the Ti / SnO2-Sb electrode, the conductivity of the Ti / SnO2-Sb electrode can be greatly improved, and the treatment capacity of the Ti / SnO2-Sb electrode for wastewater containing organic pollutants can be greatly improved. The removal rate of the Ti / SnO2-Sb-Tb electrode for moxifloxacin reaches more than 84%, while the removal rate of the conventional Ti / SnO2-Sb electrode for moxifloxacin is only 58.4%, and the removal rate of the Ti / SnO2-Sb-Ho electrode doped with other rare earth elements for moxifloxacin is 74.1%, which further shows that the doping of the rare earth element Tb in the Ti / SnO2-Sb electrode can greatly improve the treatment capacity of the electrode for wastewater containing organic pollutants.

The application discloses a colorimetric copper ion fluorescent probe and synthesis and application thereof, which has a fluorophore and a copper ion recognition group, wherein the copper ion recognition group is one of commercial drugs of norfloxacin, levofloxacin, moxifloxacin and gatifloxacin. The copper ion fluorescent probe can be used for qualitative and colorimetric detection of copper ions, and is especially used in the fields of solution / cell / tissue / living body imaging, biological labeling or sensing.

The invention provides a preparation method of a moxifloxacin side chain key intermediate, and belongs to the technical field of medical intermediate production, and the preparation method comprises the following steps: firstly salifying a compound 1 and L-(+) tartaric acid in proportion, dissociating the precipitated solid to obtain a compound 3, concentrating the filtrate, and simply refining to obtain a compound 2 with ee value of 100%, and the single resolution yield is 39%. In addition, the compound 3 is subjected to racemization to obtain a compound 1, and then the compound 1 is split again; and the yield can reach 85% or above after repeated cyclic resolution. L-(+) tartaric acid is used for resolution, a product with a high ee value is obtained in combination with a simple refining process, the resolution yield is improved to a certain extent, and the production cost is reduced.

This invention relates to a method for preparing 6-benzyl-1,2,3,4-tetrahydro-6H-pyrrolo[3,4-B]pyridine-5,7-dione and its application. The method for preparing 6-benzyl-1,2,3,4-tetrahydro-6H-pyrrolo[3,4-B]pyridine-5,7-dione involves reacting (1R,6S)-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4,3,0]nonane in an organic solvent under blue light irradiation with the aid of a photosensitizer and an oxidizing agent to obtain 6-benzyl-1,2,3,4-tetrahydro-6H-pyrrolo[3,4-B]pyridine-5,7-dione. This preparation method not only has mild reaction conditions, short reaction time, simple operation, and environmental friendliness, but also has high product conversion rate and good selectivity. It can be used for large-scale industrial production and can be better applied to the synthesis of moxifloxacin, thereby improving the utilization rate of raw materials in the synthesis of moxifloxacin.

An apparatus for imaging examination of cells on a surface of living tissue using moxifloxacin. includes: a light source emitting light towards living tissue stained with moxifloxacin; a photographing unit photographing the living tissue subjected to fluorescence excitation by the light emitted from the light source; a lens unit controlling the light emitted from the light source or a fluorescence path of moxifloxacin excited by the light; an objective lens controlling a focus of the photographing unit; an active lens disposed between the objective lens and the photographing unit and changing a focal position on the living tissue; and an image generator performing image processing of a cell image of the living tissue photographed by the photographing unit to generate an in-focus image, in which the entirety of the cell image is in focus.

The present invention relates to a lipid-based formulation for topical ophthalmic use to increase the bioavailability of antibiotics in intraocular tissues, wherein said formulation comprises: Moxifloxacin (M), polyethylene glycol (PEG)-12 glyceryl dimyristate and ethyl alcohol, polyethylene glycol (15)-hydroxystearate (Kolliphor® HS15), anhydrous citric acid and sodium citrate dihydrate. The compositions of the invention contain an effective amount of moxifloxacin (M), 0.001 to 1 mg, in other words, 0.0001 to 0.1% (w / v), polyethylene glycol (PEG)-12 glyceryl dimyristate which is used as a structural component of liposomes in a concentration of 5-15% (w / v) and ethyl alcohol which is used as an organic solvent in a concentration of 0.7 to 2.1% (v / v). Furthermore, the formulation contains 2.5 to 7.5% (w / v) of polyethylene glycol (15)-hydroxystearate (Kolliphor® HS15) as a non-ionic solubiliser and emulsifying agent. Likewise, the aqueous compositions of the present invention optionally comprise more excipients selected from the group consisting of buffering agents, pH-adjusting agents and preservatives. Anhydrous citric acid (0.04 to 0.16%) and sodium citrate dihydrate (0.23 to 0.69%) are used as buffers.